Topsalysin (Synonyms: PRX-302)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Topsalysin  (Synonyms: PRX-302)

Topsalysin 是一种 PSA 激活的原蛋白,也是一种与人前列腺特异性抗原融合的孔隙形成蛋白 (合成原气溶素)。Topsalysin 对小鼠模型的肿瘤生长有抑制作用。

  • Topsalysin                                          (Synonyms: PRX-302)
  • Topsalysin                                          (Synonyms: PRX-302)

  1. Topsalysin                                          (Synonyms: PRX-302)
  2. Topsalysin                                          (Synonyms: PRX-302)

CAS No. : 917121-25-6

规格 是否有货
1 mg 询价
5 mg 询价

* Please select Quantity before adding items.

Topsalysin 相关产品

同靶点产品:

同靶点蛋白产品:

生物活性

Topsalysin is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle[1].

种属

Aeromonas hydrophila

体外研究
(In Vitro)

Topsalysin (19 pM-10 nM; 48 小时) 对 LNCaP, PC3, DU145 和 TSU 细胞显示前列腺特异性抗原 (PSA) 依赖性毒性[1]

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Topsalysin 相关抗体:

体内研究
(In Vivo)

Topsalysin (肿瘤内注射; 1-10μg /鼠标; 单次剂量) 抑制小鼠的肿瘤生长[1]
Topsalysin (0.35、4.1、25.8 μg/kg, 25 μL; 腹腔注射; 单剂量) 可杀死食蟹猴前列腺注射部位高达 50% 的细胞[1]

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice (6-week-old) subcutaneously bearing tumors[1]
Dosage: 0, 1, 5, and 10 μg
Administration: Intratumor injection; single dose; measured tumor sizes at first day and twice weekly for 28 days
Result: Showed prostate-specific antigen (PSA)-dependent toxicity in mice.

Clinical Trial

CAS 号

917121-25-6

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Topsalysin                                          (Synonyms: PRX-302)
    proaerolysin (engineered with a PSA cutting site)-hexahistidine
纯度 & 产品资料
Data Sheet (521 KB) 抗体抑制剂使用指南 (1152 KB)

参考文献
  • [1]. Williams SA, et al. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 7;99(5):376-85.  [Content Brief]

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务